Novo Nordisk: positive phase 3 results for type-2 diabetes.
(CercleFinance.com) - A phase 3 study showed that Novo Nordisk's semaglutide is superior to Lilly's dulaglutide on glucose control and weight loss in people with type-2 diabetes, the Danish drugmaker said on Thursday.
According to the trial results, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide, the firm said.
In the meantime, people treated with 1.0 mg semaglutide experienced a statistically significant and superior reduction of 1.8% compared with a reduction of 1.4% with 1.5 mg dulaglutide.
Using the American Diabetes Association (ADA) targets, 69% of people treated with 0.5 mg semaglutide compared with 52% of people treated with 0.75 mg dulaglutide reached the treatment goal.
Novo Nordisk thinks semaglutide could set "a new standard for treatment of type-2 diabetes".
Novo Nordisk shares, which are listed in Copenhagen were up 2.1% at 292.2 Danish kroner after the results.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
According to the trial results, 0.5 mg semaglutide achieved a statistically significant and superior reduction of 1.5% compared with a reduction of 1.1% with 0.75 mg dulaglutide, the firm said.
In the meantime, people treated with 1.0 mg semaglutide experienced a statistically significant and superior reduction of 1.8% compared with a reduction of 1.4% with 1.5 mg dulaglutide.
Using the American Diabetes Association (ADA) targets, 69% of people treated with 0.5 mg semaglutide compared with 52% of people treated with 0.75 mg dulaglutide reached the treatment goal.
Novo Nordisk thinks semaglutide could set "a new standard for treatment of type-2 diabetes".
Novo Nordisk shares, which are listed in Copenhagen were up 2.1% at 292.2 Danish kroner after the results.
Copyright (c) 2017 CercleFinance.com. All rights reserved.